News
Save on some of our parenting editors' favorite gear with these Amazon Prime Day baby deals. Some of our top picks include 36 ...
Summit Therapeutics has revealed that a second pivotal trial of its Akeso-partnered PD-1xVEGF bispecific ivonescimab has failed to show an improvement in overall survival in a lung cancer trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback